KalVista Pharmaceuticals Lands $33,000,000 Series B Funding

  • Feed Type
  • Date
    7/23/2015
  • Company Name
    KalVista Pharmaceuticals
  • Mailing Address
    75 Arlington Street Boston, MA 02116 USA
  • Company Description
    KalVista is a research-led pharmaceutical company focused on the discovery, development and commercialization of small molecule serine protease inhibitors as new treatments for diseases with significant unmet need.
  • Website
    http://www.kalvista.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $33,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).
  • M&A Terms
  • Venture Investor
    RA Capital
  • Venture Investor
    Longwood Fund
  • Venture Investor
    Venrock
  • Venture Investor
    Novo Ventures
  • Venture Investor
    SV Life Sciences